Recruiting

LIFU

Sponsor:

Laureate Institute for Brain Research, Inc.

Code:

NCT07099950

Conditions

Healthy Controls

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

Low-intensity focused ultrasound

Study Details

Brief summary:

Low-intensity focused ultrasound (LIFU) has emerged as a tool to modulate the activity of deep brain structures noninvasively and reversibly, with anatomical precision. Following the results of a pilot study in which the investigators observed target engagement when LIFU was applied to the anterior limb of the internal capsule, the investigators now propose to determine the dose-response relationships of LIFU when applied to deep white matter tracts of the human brain. The investigators hope a successful study will be rapidly translatable into clinical trials seeking to understand mechanistic brain circuit-symptom relationships in major psychiatric disorders.

Conditions

Healthy Controls

Study ID

NCT07099950

Start date

Apr 22, 2025

Status verified date

Oct, 2025

Completion date

Dec, 2026

Anticipated

Primary completion date

Aug, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Age 18 to 65 years.
  • Body mass index 17-38 kg/m2.
  • Fluent English speaker, capable of providing written informed consent.
  • Overall Anxiety Severity and Impairment Scale <8 and Patient Health Questionnaire-9 <10
  • A person of childbearing potential must have a negative urine pregnancy test at screening
  • Consent that random observations of pathology are possible (e.g., brain abnormality seen during imaging).

Exclusion Criteria:

  • Inability to provide informed consent including medical, psychiatric, or other conditions that restrict the patient's following abilities: to interpret the study information, to give informed consent, to adhere to the rules of the protocol, or complete the study.
  • No telephone or easy access to telephone
  • Has active suicidal ideation (as measured by Suicide-Risk-Assessment-C-SSRS "Yes" answers to items 3, 4, or 5 Suicidal Ideation-Past 1 month section, or any "Yes" answer to any of the items of Suicidal Behavior-Past 3 months section), or any suicide attempt in the last 3 months
  • Has positive test result(s) for alcohol of abuse (including methadone, opiates, cocaine, amphetamine/methamphetamine and ecstasy), or substance use disorder including alcohol, stimulants, sedatives, and cannabis exceeding mild severity in the last 6 months
  • Has a lifetime APA Diagnostic and Statistical Manual of Mental Disorders (DSM)-5th edition including major depression, generalized anxiety disorder, specific phobias, panic disorder, post-traumatic stress disorder, schizophrenia spectrum and other psychotic disorders, obsessive-compulsive disorder, or bipolar disorder.
  • Benzodiazepines or anticonvulsants in the 7 days prior to participation.
  • MRI contradictions as detected by the MRI Safety Screen including claustrophobia and unwillingness and inability to complete scans (e.g., unable to lie on one's back for 60 mins.
  • Clinical history of relevant structural pathology of the central nervous system, including Parkinson's disease, multiple sclerosis, and brain malignant neoplasia.
  • History of unstable liver or renal insufficiency; significant and unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, hematological, rheumatological, or metabolic disturbance; or any other condition that, in the opinion of the investigator, would make participation not be in the best interest (e.g., compromise the well-being) of the subject or that could prevent, limit or confound the protocol-specified assessments, including uncontrolled diabetes mellitus (ss evidenced by fasting glycemia ≥ 120 mg/dL or hemoglobin A1c ≥ 6.5%) or hypertension (as evidenced by two consecutive readings ≥ 140/90 mmHg) to ensure medical stability throughout this longitudinal study.
  • Moderate-to-severe traumatic brain injury or any other clinical neurocognitive disorder.
  • Clinical history of at least minor neurocognitive disorder of any origin.
  • Prescription of a medication outside of the accepted range, as determined by best clinical practices and current research.
  • Use of any psychotropic medication.
  • Unwillingness or inability to complete any major aspects of the study protocol.
  • Prior neurosurgery.
  • Non-correctable vision or hearing.

Study Design

Enrollment

66 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Single Dose (1-epoch)

An 80-second train of 20-millisecond bursts of ultrasound (0.5 MHz), repeated every 200 milliseconds (400 bursts). It is estimated a 75% tissue attenuation of energy when the ultrasound wave reaches its target, therefore the investigators will set the free-field Intensity Spatial-Peak Pulse-Average (ISPPA) at 9.04 Watt /cm2 or 518 kPascal (to achieve 2.26 Watt/cm2 estimated derated ISPPA). Any modeling of actual energy delivery will be made a posteriori employing BabelBrain® software embedded in the Brainsight® neuronavigation system.

experimental: Multiple Doses (3-epoch)

Three 80-second trains of 20-millisecond bursts of ultrasound (0.5 MHz), repeated every 200 milliseconds (400 bursts) will be administered, separated by 30 seconds each. Again, it is estimated a 75% tissue attenuation of energy when the ultrasound wave reaches its target, therefore the investigators will set the free-field Intensity Spatial-Peak Pulse-Average (ISPPA) at 9.04 Watt /cm2 or 518 kPascal (to achieve 2.26 Watt/cm2 derated ISPPA). See above for a posteriori acoustic energy modeling.

Interventions

Low-intensity focused ultrasound

80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, administered as a single dose (1-epoch), or in multiple doses (3-epoch).

Primary outcome measure

  • Post-Sonication Changes in Tissue Engagement [ Time Frame: Pre- vs up to 30 minutes post-sonication for 1-epoch vs 3-epoch LIFU. ]

Central Contacts and Locations

Central contacts

Salvador M Guinjoan, MD, PhD

918-502-5119sguinjoan@laureateinstitute.org

Danielle E Clark, MA

918-701-9610dclark@laureateinstitute.org

Locations

Laureate Institute for Brain Research

Recruiting

Tulsa, Oklahoma, United States, 74136

Contacts

Salvador M Guinjoan, MD, PhD

918-502-5119sguinjoan@laureateinstitute.org

Danielle E Clark, MA

918-701-9610dclark@laureateinstitute.org

More Information

Sponsor

Laureate Institute for Brain Research, Inc.

Last update posted

Oct 16, 2025

Last verified

Oct, 2025

Keywords

  • Low-Intensity Focused Ultrasound
  • Functional Connectivity

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Laureate Institute for Brain Research, Inc. on 2025-10-16.